C1AG
GILD icon

Client 1st Advisory Group’s Gilead Sciences GILD Stock Holding History

Client 1st Advisory Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Buy
1,717
+117
+7% +$15.4K 0.06% 137
2026
Q1 		$223K Buy
+1,600
New +$224K 0.07% 129

Other funds holding GILD

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

Client 1st Advisory Group's GILD Position: Q2 2026 in Review

Client 1st Advisory Group increased its Gilead Sciences (GILD) stake by 7.3% in Q2 2026, buying an estimated $15.4K and bringing the position to 1,717 shares worth $217K. The position accounts for 0.06% of the portfolio, ranked #137.

Client 1st Advisory Group first reported a position in GILD in Q1 2026 and has held it in 2 quarters since. The position peaked at $223K in Q1 2026. 443 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Client 1st Advisory Group held 1,717 shares of Gilead Sciences worth $217K as of Q2 2026.
  • Client 1st Advisory Group bought 117 Gilead Sciences shares in Q2 2026, an estimated $15.4K.
  • Gilead Sciences made up 0.06% of Client 1st Advisory Group's portfolio in Q2 2026, its #137 holding.
  • Client 1st Advisory Group first reported a position in Gilead Sciences in Q1 2026 and has held it in 2 quarters since.
  • Client 1st Advisory Group's Gilead Sciences position peaked at $223K in Q1 2026.
  • 443 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Client 1st Advisory Group's 13F filing for Q2 2026, filed 13 Jul 2026.